BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36575970)

  • 21. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
    Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
    Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
    Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
    Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and classification of myelodysplastic syndromes.
    Hasserjian RP; Germing U; Malcovati L
    Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
    Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts.
    Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z
    Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms.
    Chopra S; Bailey NG
    Am J Clin Pathol; 2023 Dec; 160(6):566-570. PubMed ID: 37587830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
    Maggioni G; Della Porta MG
    Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
    AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of SF3B1 Mutations in Myeloid Neoplasms.
    Gajzer DC; Yeung CCS
    Clin Lab Med; 2023 Dec; 43(4):597-606. PubMed ID: 37865505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
    Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
    Fontana D; Elli EM; Pagni F; Piazza R
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
    Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
    Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.
    Zhang Y; Wu J; Qin T; Xu Z; Qu S; Pan L; Li B; Wang H; Zhang P; Yan X; Gong J; Gao Q; Gale RP; Xiao Z
    Leukemia; 2022 Dec; 36(12):2875-2882. PubMed ID: 36224330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morphologic Characteristics of Myelodysplastic Syndromes.
    Yuen LD; Hasserjian RP
    Clin Lab Med; 2023 Dec; 43(4):577-596. PubMed ID: 37865504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
    van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
    Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.